TNF Pharmaceuticals, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a TNFA research report →
About the company
TNF Pharmaceuticals, Inc. is a clinical-stage pharmaceutical firm dedicated to developing advanced therapeutic platforms that tackle the root causes of diseases, rather than just managing symptoms. Its flagship drug platform, MYMD-1, is a small molecule currently undergoing clinical trials.
- CEO
- Mitchell Glass
- IPO
- 2014
- Employees
- 2
- HQ
- New York City, NY, US
Price Chart
- Market Cap
- $9.18M
- P/E
- -0.18
- P/S
- 0.00
- P/B
- 1.31
- EV/EBITDA
- -0.63
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -65.21%
- ROIC
- -26.68%
- Revenue
- $0 · 0.00%
- Net Income
- $-11,627,122 · 50.22%
- EPS
- $-8.66 · 99.22%
- Op Income
- $-9,847,357
- FCF YoY
- -0.99%
- 52W High
- $195.00
- 52W Low
- $3.24
- 50D MA
- $7.03
- 200D MA
- $33.82
- Beta
- 2.28
- Avg Volume
- 1.68M
Get TickerSpark's AI analysis on TNFA
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Apr 17, 25 | RAUCH GARY M | other | 75,000 |
| Apr 17, 25 | RHODES IAN | other | 25,000 |
| Apr 17, 25 | Glass Mitchell | other | 125,000 |
Our TNFA coverage
Recent articles, reports, and earnings notes.
No research on TNFA yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate TNFA report →Similar companies
Peers in the same neighborhood.